Clinical Trials

59 enrolled

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

NCT06187961 2026-05-22

CCGLC-011

42 enrolled

Carcinoma, Hepatocellular

NCT04626479 2026-05-18

MK-3475-03A

400 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT07081633 2026-05-12

TREMENDOUS-2

114 enrolled

Carcinoma, Hepatocellular

NCT04848337 2026-05-11

PLANE-PC

45 enrolled 8 charts

EndocrineNET

Neuroendocrine Tumors

NCT04164199 2026-05-08

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

404 enrolled

Advanced Malignancies

NCT04626518 2026-05-06

KEYMAKER-U03

370 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04736706 2026-05-06

MK-6482-012

1,653 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04586231 2026-05-05

MK-6482-011

747 enrolled

Carcinoma, Renal Cell

NCT05081180 2026-05-01

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

17 enrolled

CNS

Neoplasms, Central Nervous System Neoplasms

NCT05384015 2026-04-30

PEERS

46 enrolled

Thoracic

Lung Neoplasms

NCT04887805 2026-04-29

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer

28 enrolled

Pancreatic Neoplasms

NCT04207086 2026-04-23

Neo PeLe

21 enrolled

Melanoma

NCT04393350 2026-04-20

Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

18 enrolled 12 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04745988 2026-04-09

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

43 enrolled

Stomach Neoplasms

NCT05696548 2026-04-09

Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)

51 enrolled

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT04305054 2026-04-08

KEYMAKER-U02

315 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT04869137 2026-04-08

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

26 enrolled 9 charts

Skin Neoplasms, Carcinoma, Merkel Cell

NCT05301842 2026-04-07

EMERALD-3

760 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04039607 2026-04-06

CheckMate 9DW

732 enrolled 1 FDA

Carcinoma, Hepatocellular

NCT04008797 2026-03-24

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

GastrointestinalGynecologic

301 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03950609 2026-03-19

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

36 enrolled

EndocrineNET

Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT05824468 2026-03-10

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Uterine Cervical Neoplasms

NCT05824481 2026-03-10

Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

32 enrolled

Endometrial Neoplasms

NCT05012371 2026-03-05

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

90 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT04321954 2026-02-27

Lenvatinib in Locally Advanced Invasive Thyroid Cancer

EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT02811861 2026-02-23

CLEAR

1,069 enrolled 12 charts 1 FDA

Carcinoma, Renal Cell

NCT04171622 2026-02-17

Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

25 enrolled

EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT04781088 2026-02-11

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

38 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05113186 2026-01-29

LENVABLA

32 enrolled

Carcinoma, Hepatocellular

NCT05036434 2026-01-23

ACCOMPLISH

Endocrine

Adrenocortical Carcinoma

NCT05273554 2026-01-12

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

15 enrolled

Tumor-Agnostic

Adenocarcinoma, Neoplasms

NCT05030506 2025-12-18

MK-6482-010

45 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05296512 2025-12-16

Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer

Ovarian Clear Cell Carcinoma

NCT04949256 2025-12-15

MK-7902-014

864 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT05433116 2025-12-02

Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC

50 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05282901 2025-11-24

PLUME

51 enrolled

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT05899049 2025-11-10

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

249 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04209660 2025-10-07

Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers

64 enrolled

Head & Neck

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT02562118 2025-09-25

Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer

40 enrolled

Breast

Breast Neoplasms

NCT04929392 2025-09-04

Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer

3 enrolled

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma

NCT05822752 2025-08-14

LIVIGNO-1

130 enrolled

Carcinoma, Hepatocellular, Neoplasms

NCT05114421 2025-08-07

Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients

High Grade Fallopian Tube Serous Adenocarcinoma

NCT05078931 2025-07-30

A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients

35 enrolled

Thoracic

NSCLC

NCT04522323 2025-07-25

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

67 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell

NCT05308901 2025-07-25

Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma

6 enrolled 11 charts

Uveal Melanoma, Melanoma

NCT02780310 2025-06-05

Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma

33 enrolled

Carcinoma, Adenoid Cystic

NCT04976634 2025-04-06

MK-6482-016

730 enrolled

Tumor-Agnostic

Neoplasms

NCT04287829 2024-11-05

PEMMELA